ArticleCancer prevention research (Philadelphia, Pa.)2026
Yes, It Is Worth It: Consider Participant Experiences in the Design of Future Trials.
Article in Cancer prevention research (Philadelphia, Pa.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Measuring toxicity better: patient-reported outcome-informed calibration for CTCAE assessment.Translational cancer research · 2026Article
Corrections and comments
- Comment on
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical cancer prevention and interception trials target high-risk populations and require agents with favorable risk-to-benefit ratios. Participant experiences are crucial in trial design, as highlighted in this issue of Cancer Prevention Research by Zahrieh and colleagues, which applied the "Was It Worth It?" questionnaire to evaluate participants' experiences in cancer chemoprevention trials. This study is the first examination of satisfaction in early-phase chemoprevention trials for high-risk individuals. This timely study underscores the need to assess and integrate participant and advocate feedback in completed, ongoing, and future trials. This spotlight commentary emphasizes the importance of participant experiences in enhancing trial designs for cancer prevention and interception. See related article by Zahrieh et al., p. 11.
Indexed as
Identifiers
41492232What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.